Valeant increases proposal for Allergan merger by about 21% per share

Valeant Pharmaceuticals has increased its April 22 proposal to acquire Allergan, the company announced in a press release.The revised proposal increases Valeant’s cash consideration by $10 per share, or about 21%, to $58.30.

Full Story →